Boston Scientific Corp. (BSX) announced that the U.S. District Court for the District of Delaware has found all four patents in a suit involving Johnson & Johnson (JNJ) to be invalid.
As part of a 2007 suit, Johnson & Johnson alleged that Boston Scientific's PROMUS Everolimus-Eluting Coronary Stent System infringed these four patents, known as the Wright/Falotico patents. The patents relate to coatings , drug and polymer, for drug-eluting stents.
The court ruled that a trial on the four patents, which was scheduled to begin February 9, will not proceed.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.